cagrilintide novo nordisk Nordisk's next-gen obesity drug CagriSema trial results disappoint investors Novo Nordisk's next-generation weight-loss drug

Cagrilintide is a synthetic peptide analogue, developed from amylin to improve stability and extend its activity duration

The peptide sequence consists of fifteen amino acids arranged as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, forming a stable molecular structure that demonstrates resistance to enzymatic degradation compared to other peptide compounds

By preserving only a Tyr-Ile dipeptide (from angiotensin IV) flanked by hexanoic chains, Harding's laboratory achieved three simultaneous objectives: BBB penetration, stability against aminopeptidases, and oral bioavailability

The transfer of the exosomal cargo (RNAs and proteins) may induce functional modifications in the recipient cells

Inside the Capsule: Ingredients and Quality Breakdown of Healthletic BPC-157 A Closer Look at the Active Ingredient At the core of Healthletic's formula lies its unique active ingredient: BPC-157 (Body Protection Compound-157) in Arginine Salt form